Regulatory Framework of Drug-Device Combination
drug_device_combination_1
The advances in technology continue to merge different types of products and the historical lines of separation between medical devices and medicinal products are getting thinner. Products combining medicinal products and medical devices are regulated either by Regulation (EU) 2017/745 (MDR) or by Directive 2001/83/EC.

What is a drug-device combination product?

Drug-device combination products (DDCs) are medicinal products which contain one or more medical devices as an integral part of their composition or medicinal products which do not incorporate medical devices in an integral manner, but which require medical devices for their administration, correct dosing or use.

Relevant definitions

The combination of a medicinal product and a medical device can constitute an integral product or a non-integral product.

Integral products – An integral product can be:

  • A device which incorporates a substance as an integral part that, if used separately, is considered a medicinal product and the substance action is principal. Examples include medicinal products with embedded sensors.
  • A device intended to administer a medicinal product that constitutes a single integral product intended exclusively for use in combination and which is not reusable. Examples include single-use pre-filled syringes, drug-releasing intra-uterine devices and single-use pre-filled dry powder inhalers.

Non-integral products – The components (medicinal product and device) of non-integral products are not physically integrated during manufacturing, but are combined for administration. Non-integral products include co-packaged products and referenced products:

  • Co-packaged – The medicinal product and the medical device are placed on the market packed together into a single pack.
  • Referenced – The medicinal product information (SmPC and/or package leaflet) refers to a specific medical device to be used which is obtained separately.

Examples of non-integral DDCs include: cups, spoons and syringes for oral administration, refillable pens and injectors using cartridges, nebulisers, vaporisers, pumps for medicinal product delivery and electronic tablet dispensers.

Regulatory framework

Integral products are regulated by EU pharmaceutical legislation (Directive 2001/83/EC or Regulation (EC) No 726/2004), under which the medicinal product must obtain a marketing authorisation. Regarding the device part, Article 117 of the MDR states that it should be included evidence of the conformity with the relevant General Safety and Performance Requirements (GSPRs) (MDR Annex I). With this Article, marketing authorisation application should include a CE certificate for the device or, in case it is not CE marked and the involvement of a notified body is required according with the MDR, the applicant must include an opinion from a notified body on conformity of device with the GSPRs.

However, if the device incorporates a substance as an integral part that, if used separately, is considered a medicinal product, but the action of the substance is ancillary to that of the device, the product shall be assessed in accordance with the MDR requirements. Determining whether the substance “is ancillary” shall consider the substance availability in the human body and/or the quantity that is available.

If the products are co-packaged or referenced, the medicine is regulated by Directive 2001/83/EC or Regulation (EC) No 726/2004, and the device part must be CE marked in accordance with the MDR.

In case the device is intended to administer a medicinal product, it is regulated by the MDR, but the medicinal product part is still governed by Directive 2001/83/EC or Regulation (EC) No 726/2004. However, if the device is intended to administer a medicinal product, but it constitutes a single integral product intended exclusively for use in combination and not reusable, the product is regulated by Directive 2001/83/EC and Regulation (EC) No 726/2004, and the device part must include evidence of the conformity with the relevant GPSRs.

Source: MDCG 2022–5 Guidance on borderline between medical devices and medicinal products under Regulation (EU) 2017/745 on medical devices, April 2022

Challenges

The development of combination products requires a collaborative approach. Sponsors have typically expertise in pharmaceutical market or in medical devices market, and that can pose a challenge once they have to acquire the necessary expertise prior to start developing their products.

When deciding on the regulatory status of a combination product, the first step is to establish whether the product is an integral product. Other essential step in the regulatory approach to combination products is to clearly define the product intended purpose and mode of action to understand which part of the combination is principal and which is ancillary.

DDCs can also be associated with higher resources consumption and time expenditure, because it is necessary to assure that performance and safety are met for both parts of the product, individually and in combination.

References:

  1. Regulation (EU) 2017/745, on medical devices
  2. European Medicines Agency (EMA) Guideline on quality documentation for medicinal products when used with a medical device, 22 July 2021
  3. MDCG 2022 – 5 Guidance on borderline between medical devices and medicinal products under Regulation (EU) 2017/745 on medical devices, April 2022

further
reading

medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »